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Clinical and Laboratory Standards Institute (CLSI) conditions for testing the 43 
susceptibilities of pathogenic Sporothrix species to antifungal agents are based on a 44 
collaborative study that evaluated five clinically relevant isolates of Sporothrix schenckii sensu 45 
lato and some antifungal agents. With the advent of molecular identification, there are two basic 46 
needs: to confirm the suitability of these testing conditions for all agents and Sporothrix species 47 
and to establish species-specific epidemiologic cutoff values (ECVs) or breakpoints (BPs) for 48 
these species. We collected available CLSI MICs/MECs of amphotericin B, five triazoles, 49 
terbinafine, flucytosine and caspofungin for 301 Sporothrix schenckii sensu stricto, 486 S. 50 
brasiliensis, 75 S. globosa and 13 S. mexicana molecularly identified isolates. Data were 51 
obtained in 17 independent laboratories (Australia, Europe, India, South Africa, South and North 52 
America) using conidial inoculum suspensions and 48-72 h of incubation at 35°C. Sufficient and 53 
suitable data (modal MICs within 2-fold concentrations) allowed the proposal of the following 54 
ECVs for S. schenckii and S. brasiliensis, respectively: amphotericin B 4 and 4 µg/ml, 55 
itraconazole 2 and 2 µg/ml; posaconazole 2 and 2 µg/ml; and voriconazole 64 and 32 µg/ml; 56 
ketoconazole and terbinafine ECVs for S. brasiliensis were 2 and 0.12 µg/ml, respectively. 57 
Insufficient or unsuitable data precluded the calculation of ketoconazole and terbinafine ECVs 58 
for S. schenckii as well as ECVs for S. globosa and S. mexicana or any other antifungal agent. 59 
These ECVs could aid the clinician in identifying potentially resistant isolates (non-wild type) 60 




Sporotrichosis is considered a relatively uncommon granulomatous infection of the 65 
cutaneous and subcutaneous tissue, although dissemination to other deep-seated organs has 66 
been reported (1,2). The first case of sporotrichosis was documented in the United States in the 67 
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late 1800s by Benjamin Schenck (3,4). This case was followed by worldwide reports as well as 68 
numerous outbreaks (e.g., in the South African mines in the 1920s and 1930s, among children 69 
in relatively remote areas of Peru, the Brazilian case clusters, and in the USA (5-8). In addition, 70 
several feline outbreaks caused by Sporothrix brasiliensis with transmissions from cat to human 71 
to cat have been reported in Brazil (7,8). Most other outbreaks or infections have been 72 
associated with traumatic inoculation of vegetative materials and/or soil. Until recently, all cases 73 
were attributed to S. schenckii, according to phenotypic identification (macro and microscopic 74 
studies, carbohydrate assimilations, and conversion to the yeast phase). The advent of 75 
molecular methodologies and the use of internal transcribed spacer (ITS), region sequence 76 
analysis of chitin-synthase, ß-tubulin and calmodulin (CAL) genes indicated that there were 77 
various cryptic species nested in the medically relevant clade. The taxon was considered as the 78 
Sporothrix schenckii species complex (8-12). Therefore, sporotrichosis is caused by different 79 
pathogenic species, including the three clinically relevant species evaluated in the present 80 
study: S. schenckii  sensu stricto (referred from now only as S. schenckii), S. brasiliensis, and S. 81 
globosa. We also evaluated one rare species in the environmental clade, S. mexicana (10,11). 82 
 83 
The recommended therapeutic agents for the treatment of human sporotrichosis are 84 
itraconazole, amphotericin B and its lipid formulations (invasive/disseminated disease), 85 
terbinafine, and fluconazole; the saturated solution of potassium iodide has been an alternative 86 
choice for lymphocutaneous/cutaneous infections (2,13-18). Ketoconazole is not used as much 87 
given its low efficacy and potentially severe side effects (13,16). Among the newer triazoles, in 88 
vivo and in vitro activity has been reported with posaconazole in combination with amphotericin 89 
B, while voriconazole has not been considered a therapeutic choice for these infections due to 90 
its high MICs (19,20). 91 
 92 
The Clinical and Laboratory Standards Institute (CLSI) has described testing conditions 93 
for the “filamentous phase of the S. schenckii species complex”, because the initial CLSI 94 
collaborative evaluation predated molecular studies, which only included five isolates that were 95 
documented as “S. schenckii” (21,22). Therefore, the species of Sporothrix are not mentioned in 96 
the CLSI M38-A2 document (21). In addition, interpretive MIC/MEC categories, either formal 97 
breakpoints (BPs) or epidemiological cutoff values (ECVs), have not been established for any of 98 
Sporothrix species. Method-dependent and species-specific ECVs should identify the non-wild 99 
type (non-WT) isolates with reduced susceptibility to the agent being evaluated due to acquired 100 
mutational or other resistance mechanisms (23,24). Whilst ECVs would not predict the clinical 101 
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success to therapy, these endpoints could identify those isolates less likely to respond to the 102 
specific agents. We have collected available MICs/MECs of nine antifungal agents from 17 103 
laboratories for molecularly identified isolates of four Sporothrix species. These MIC/MEC 104 
values represent the antifungal susceptibility of the two more prevalent species (S. schenckii 105 
and S. brasiliensis) as well of those of S. globosa and S. mexicana to the different agents as 106 
determined by the CLSI M38-A2 method (21). Although the in vitro data were obtained in 17 107 
laboratories, the isolates originated from different geographical areas (Australia, Europe, India, 108 
South Africa, and both South and North American countries).  109 
 110 
The purpose of the present study was (i) to pool available MIC/MEC data determined by 111 
the broth microdilution M38-A2 method originating from 17 independent laboratories for S. 112 
schenckii, S. brasiliensis, S. globosa and S. mexicana; (ii) to define the WT susceptibility 113 
MIC/MEC distributions of amphotericin B, five triazoles, terbinafine, flucytosine, and 114 
caspofungin; (iii) to assess the suitability of these distributions for ECV calculation (including 115 
interlaboratory modal agreement); and (iv) to propose CLSI ECVs for two of those species (S. 116 
schenckii and S. brasiliensis) when the agent/species combination comprised >100 MICs that 117 
originated in 3 to 9 laboratories. MICs of S. globosa and S. mexicana that originated in 3 to 4 118 
laboratories were also listed when the distribution comprised at least 10 isolates from >3 119 
centers; caspofungin, flucytosine and fluconazole data were summarized in the text. 120 
 121 
Results and Discussion   122 
 123 
CLSI BPs, which reliably predict clinical response to therapy, are not available for any 124 
filamentous (mould) species including the Sporothrix species. While the establishment of BPs 125 
requires, in addition to other parameters, the clinical correlation of both high and low in vitro 126 
results with in vivo data, ECVs are based solely on in vitro data obtained in multiple laboratories 127 
(24,25). ECVs or BPs are needed in order to identify the potential in vitro resistance to the agent 128 
under evaluation. Although the scarcity of clinical data has precluded the establishment of CLSI 129 
BPs for mould testing, several ECVs (e.g., for certain species of Aspergillus, Fusarium and the 130 
Mucorales) are available (23,24,26,27). ECVs should distinguish the two populations (WT and 131 
non-WT) that are present in the MIC/MEC distribution of a species and agent combination. 132 
ECVs for S. brasiliensis and some agents were recently reported using data from a single 133 
laboratory (28). However, the definition of ECVs using data from multiple laboratories allows the 134 
evaluation of modal (more frequent value in each MIC/MEC distribution) compatibility among the 135 
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individual distributions included in the pool (a CLSI requirement) (24). To our knowledge, ECVs 136 
have not been defined for any other Sporothrix species; therefore, we collected available MIC/ 137 
MEC data for S. schenckii, S. brasiliensis, S. globosa and S. mexicana from 17 laboratories 138 
worldwide in order to propose ECVs for several antifungal agents.  139 
 140 
Another requirement for the definition of ECVs is that the MIC/MEC data must be 141 
accompanied by results for at least one of the quality control (QC) or reference strains (23,24). 142 
Examination of the results for QC or reference isolates in our study demonstrated that 143 
discrepant MICs for the QC and reference strains (21), although uncommon, were obtained in 144 
some laboratories as follows: (i) lower amphotericin B, itraconazole and posaconazole MICs 145 
than the expected limits for the QC Candida krusei ATCC 6258 strain from one laboratory; (ii) 146 
lower amphotericin B and posaconazole MICs for the QC isolate Paecilomyces variotii ATCC 147 
MYA-3630 and the reference Aspergillus flavus ATCC 204304 strains, respectively, from 148 
another laboratory. As far as we know, MIC limits have not been established for terbinafine and 149 
any fungal strain. However, the laboratories that provided terbinafine MICs used as their internal 150 
controls some of the QC or reference isolates. Terbinafine MICs ranged from 0.25 to 1 µg/ml 151 
and 0.25 to 0.5 µg/ml for both A. fumigatus ATCC MYA-3626 and A. flavus ATCC 204304, 152 
respectively. Nevertheless, the MIC ranges for the C. krusei ATCC 6258 (2 to 64 µg/ml) and to 153 
certain extent for C. parapsilosis ATCC 22019 (0.01 to 0.5 µg/ml) were wider than the approved 154 
ranges for QC or reference isolates (21). These results indicated that both Candida QC strains 155 
could be unsuitable as either QC or reference isolates for terbinafine, but future collaborative 156 
studies should establish control guidelines for this agent.  157 
 158 
Although we received MIC/MEC data from 17 laboratories for the four Sporothrix species 159 
evaluated in the present study, distributions for each species/agent combination were not 160 
collected from each center. In addition, the following unsuitable distributions were excluded: (i) 161 
aberrant (mode at the lowest or highest concentration tested) or distributions where the mode is 162 
not obvious (e.g., distributions having two or more modes), (ii) when MICs for the QC isolate(s) 163 
were outside the recommended limits, or (iii) the mode of a particular distribution was more than 164 
one concentration/dilution than the global mode (23,24). In addition, we only incorporated data 165 
obtained by the same and unmodified M38-A2 testing parameters as per responses to the 166 
survey sent to each laboratory (described below) as follows: (i) MIC distributions that were 167 
obtained using conidial suspensions as the inoculum; (ii) MICs obtained after 48 to 72 h of 168 
incubation at 35°C; and (iii) by the standard growth inhibition criteria for each agent. Those are 169 
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essentially the M38- A2 testing guidelines for obtaining in vitro data for a variety of non-170 
dermatophyte mould species and agents; the exception is terbinafine (only evaluated in 171 
multicenter studies for dermatophytes by the CLSI reference method) (21). However, regarding 172 
the Sporothrix species, the testing guidelines were based on the multicenter evaluation that 173 
included five isolates of S. schenckii sensu lato and four (amphotericin B, fluconazole, 174 
itraconazole and ketoconazole) of the nine agents evaluated in the present study (21,22). Since 175 
collaborative studies have not been conducted with molecularly identified isolates and QC data 176 
are not available for terbinafine, the present collaborative study provides important corroboration 177 
about the testing conditions that could yield the most comparable values for six of the nine 178 
agents (best interlaboratory modal agreement). These parameters could serve as the basis for 179 
further and related studies for evaluating other agents and species, e.g., S. globosa and S. 180 
mexicana. 181 
 182 
The MIC distributions of the four Sporothrix species and six of the nine agents evaluated 183 
are depicted in Table 1. The modal MICs ranged between 0.5 and 2 µg/ml for most of the 184 
species and agent combinations; the exceptions were the higher voriconazole (8 to 16 µg/ml) 185 
and the lower terbinafine modes for S. brasiliensis and S. globosa (0.06 µg/ml). Flucytosine, 186 
fluconazole and caspofungin data were also collected for S. schenckii, S. brasiliensis and S. 187 
globosa from two to five laboratories. Although most of those distributions were either abnormal 188 
or unsuitable for ECV definition, both fluconazole and flucytosine modes were consistently at 189 
the upper end of the distribution (>32 µg/ml) for S. brasiliensis and S. schenckii, while 190 
caspofungin modes were ~1 µg/ml (data not listed in Table 1). While abundant in vitro data are 191 
found in the literature in addition to those summarized in Table 1, these studies (i) predated the 192 
advent of molecular identification, (ii) reported MIC/MEC data mostly for S. schenckii and S. 193 
brasiliensis, and (iii) MICs were obtained for either the yeast or filamentous phase or by 194 
modified versions of the CLSI reference method (e.g., supplemented RPMI broth [2%], 30°C 195 
incubation, longer incubation times) (29-32). Although some MIC ranges in Table 1 were wider 196 
than those in prior studies, owing perhaps to the larger number of isolates (e.g., > 200 versus < 197 
100) and different testing conditions, the antifungal susceptibility trend of those species to the 198 
various agents is similar. When MICs that were obtained using both the yeast and conidial 199 
phases of S. schenckii were compared, the yeast phase yielded lower amphotericin B and 200 
itraconazole MICs, while terbinafine MICs were similar or the same (30). There was a need to 201 
ascertain which testing conditions yield the most reproducible results. Our collaborative study 202 
provides such corroboration at least for the two more prevalent species and clinically relevant 203 
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therapeutic agents. In addition, our results suggest that the incubation time for S. globosa needs 204 
to be longer and that further evaluation is needed for S. mexicana, among other species.  205 
 206 
Table 2 summarizes MIC ranges, modes and more importantly our proposed ECVs for 207 
the species and agents with sufficient data to fulfill the current criteria (> 100 MICs of each 208 
agent and species obtained in > 3 independent laboratories) for establishing method-and 209 
species-dependent ECVs by the iterative statistical method (23,24). The CLSI has selected the 210 
97.5% over the 95% ECVs, both values were calculated and documented. As expected, the 211 
highest ECVs were for voriconazole versus S. schenckii and S. brasiliensis (64 and 32 µg/ml, 212 
respectively) and the lowest value for terbinafine and S. brasiliensis (0.12 µg/ml). Sufficient and 213 
suitable terbinafine MIC data were not available to calculate the terbinafine ECV for S. schenckii 214 
according to the current criteria; this species/agent combination needs to be further evaluated. 215 
We are also proposing ECVs of 4 µg/ml for amphotericin B and ECVs of 2 µg/ml for three 216 
triazoles and both S. schenckii and S. brasiliensis. The high ECVs for these two species (e.g., 217 
amphotericin B and voriconazole ECVs above expected and achievable serum levels) indicate 218 
their resistant nature, as was the case for certain species among the Mucorales and Fusarium 219 
spp. (26,27). Although the ECV is not a predictor of clinical response to therapy, the high values 220 
suggest that isolates of these species could be unresponsive to therapy with these agents. On 221 
the other hand, categorization of an isolate as WT does not necessarily signify that it is 222 
susceptible to or treatable by the agent under evaluation. 223 
 224 
Unfortunately, among the moulds, genetic information concerning the mechanisms of 225 
resistance is mostly available for A. fumigatus and the triazoles. To our knowledge that is not 226 
the case for the clinically relevant Sporothrix species. In addition, limited data have been 227 
documented regarding the possible correlation between MICs for the Sporothrix infective isolate 228 
and the outcome of therapy with the specific agent, including amphotericin B, itraconazole or 229 
terbinafine (17,33). In one of those two studies, five patients who responded to oral itraconazole 230 
(pulse, 400 mg/day one week with a three week break) for lymphangitic and fixed cutaneous 231 
sporotrichosis, the itraconazole MICs for 4 of the 5 infecting S. schenckii isolates were either 232 
0.25 or 0.5 µg/ml (17). Those itraconazole MICs were below our proposed ECV of 2 µg/ml for 233 
this species and those strains could be considered WT strains (Table 2). In the other report, 234 
seven patients with various and persistent S. brasiliensis infections (including disseminated 235 
disease) were treated for > 13 weeks as follows: itraconazole 100 mg (3 patients), terbinafine 236 
200 mg (3 patients) and amphotericin B, followed by 800 mg of posaconazole (1 HIV-infected 237 
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patient) (33). MICs for the serial infective isolates and the clinical response to therapy were as 238 
follows: itraconazole 1 or 2 µg/ml (patients cured/infection free); terbinafine between 0.03 and 239 
0.12 µg/ml (1 of 3 patients cured); posaconazole 1 µg/ml and amphotericin B between 2 and 4 240 
µg/ml (patient died). Our proposed ECVs for S. brasiliensis and those four agents were: 2, 0.12, 241 
2 and 4 µg/ml, respectively, and thus, those infecting isolates also could be considered WT 242 
(Table 2). However, other factors related to the patient immune response or the use of adjuvant 243 
treatments (cryosurgery/curettage) could interfere with meaningful in vitro versus in vivo 244 
correlations. On the other hand, the combination of posaconazole and amphotericin B was 245 
effective in murine models of disseminated disease caused by S. schenckii or S. brasiliensis 246 
(34). The infective isolates for the murine model were WT according to our proposed ECVs. 247 
Furthermore, the role of the ECV is not to predict therapeutic outcome, but to identify the non-248 
WT strains that could be less likely to respond to therapy.  249 
 250 
In conclusion, the main role of the ECV is to distinguish between WT and non-WT 251 
isolates and aid the clinician in identifying the non-WT isolates that are potentially refractory to 252 
therapy with the agent evaluated. This is important when BPs are not available for the 253 
species/agent being evaluated, which is the case for the Sporothrix species. Based on CLSI 254 
MICs from multiple laboratories, we are proposing the following species-specific CLSI ECVs for 255 
S. schenckii and S. brasiliensis, respectively: amphotericin B, 4 and 4 µg/ml; itraconazole, 2 and 256 
2 µg/ml; posaconazole, 2 and 2 µg/ml; and voriconazole, 64 and 32 µg/ml. Our proposed 257 
ketoconazole and terbinafine ECVs for S. brasiliensis are 2 and 0.12 µg/ml, respectively. 258 
Insufficient data precluded the calculation of ketoconazole and terbinafine ECVs for S. 259 
schenckii, as well as ECVs for S. globosa and S. mexicana versus any antifungal agent. More 260 
importantly, we have corroborated that the susceptibility testing conditions described in the CLSI 261 
M38-A2 document could yield the most reliable or reproducible results for the two most 262 
prevalent species, which were based on our examination of modes from multiple laboratories.  263 
  264 
Materials and methods 265 
 266 
Isolates. The isolates evaluated were recovered from clinical specimens (mostly 267 
lymphocutaneous cutaneous [including disseminated disease] or subcutaneous lesions [>90%]) 268 
and to a lesser extent pulmonary lesions or other disseminated infections. In addition, we 269 
received S. brasiliensis isolates (cutaneous lesions) of feline origin from 4 of the 17 laboratories. 270 
MIC/MEC data for each agent were determined in each of the following centers: VCU Medical 271 
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Center, Richmond VA, USA; Universidade Federal Rural do Rio de Janeiro, Seropédica, Brasil; 272 
Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, 273 
Laboratório de Micologia and Laboratório de Pesquisa Clínica em Dermatozoonoses em 274 
Animais Domésticos , Rio de Janeiro, RJ, Brasil; Specialized Medical Mycology Center, Federal 275 
University of Ceará, Fortaleza-CE, Brazil; Department of Medical Microbiology, Postgraduate 276 
Institute of Medical Education & Research, Chandigarh, India; Department of Medical Mycology, 277 
Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India; Canisius Wilhelmina Hospital, 278 
Centre of Expertise in Mycology, Nijmegen, The Netherlands; Departamento Micologia, Instituto 279 
Nacional de Enfermedades Infecciosas “Dr. C. G. Malbrán”, Buenos Aires, Argentina; 280 
Universidad Autonóma de Nuevo León, Monterrey, Nuevo León, México; National Institute for 281 
Communicable Diseases and University of the Witwatersrand, Johannesburg, South Africa; 282 
Mycology Unit Medical School, Universitat Rovira i Virgili, Reus, Spain; Mycology Reference 283 
Laboratory, Public Health England, Bristol, UK; National Mycology Reference Centre, SA 284 
Pathology, Adelaide, Australia;.Universidade Federal de São Paulo, São Paulo, Brasil; Instituto 285 
de Biofísica, Universidade Federal do Rio de Janeiro, Brasil; and Instituto Adolfo Lutz, São 286 
Paulo, Araçatuba, and Rio Claro Laboratories, Brasil. 287 
 288 
Although data were received from 17 independent laboratories (coded 1 to 17), some 289 
MIC distributions were excluded from the study for previously discussed reasons. The isolates 290 
were identified using phenotypic and genetic approaches (e.g., temperature and nutritional 291 
tests, yeast conversion, species specific PCR and PCR-RFLP calmodulin and ß-tubulin 292 
sequencing) (10-12,35). The MIC data used for ECV definition were as follows: 301 S. schenckii 293 
and 486 S. brasiliensis isolates. Among the 486 isolates of S. brasiliensis, 261 were isolated 294 
from cats. In addition, MIC/MEC data were collected for 75 S. globosa and 13 S. mexicana, 295 
respectively. At least one of the QC isolates (C. parapsilosis ATCC 22019, C. krusei ATCC 296 
6258, or P. variotii ATCC MYA-3630) was evaluated by the participant laboratories during 297 
testing; some laboratories also evaluated the reference isolates A. flavus ATCC 204304 or A. 298 
fumigatus ATCC MYA-3626. MICs were only pooled or used for the calculation of ECVs when 299 
MICs for the QC or reference isolates were consistently within the established MIC limits as 300 
approved by the CLSI (21). 301 
 302 
In vitro susceptibility testing. MIC data for each isolate in the set that was included for 303 
analysis or depicted in Tables 1 and 2 were obtained at each center according to the CLSI M38-304 
A2 broth microdilution method (21) (standard RPMI 1640 broth [0.2% dextrose], final conidial 305 
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suspensions that ranged from 0.4x104 to 5x104 CFU/ml and an incubation at 35°C between 48 306 
to 72 h (S. schenckii, S. brasiliensis, and S. mexicana) or >72 h for S. globosa. MICs were the 307 
lowest drug concentrations that produced either complete growth inhibition (100%: amphotericin 308 
B, itraconazole, posaconazole and voriconazole) or partial growth inhibition as follows: 309 
(terbinafine [80%], fluconazole, ketoconazole and flucytosine [50%]), or morphological changes 310 
(caspofungin MECs).  311 
 312 
Data analysis. Data were analyzed by the iterative statistical analysis as previously 313 
described in various ECV reports (24-27). MIC/MEC distributions of each species received from 314 
each center were listed in electronic spreadsheets. Individual distributions were not included in 315 
the final analysis when (i) the distribution had a modal MIC at the lowest or highest 316 
concentration tested or were bimodal or when (ii) unusual modal variation (modes that were 317 
more than one dilution/concentration from the global mode) (24). Data for each species and 318 
agent were only included for the final calculation of ECVs when the total pooled distribution had 319 
> 100 isolates and originated from at least three laboratories (Tables 1 and 2).  320 
 321 
Surveys. To ascertain that the collected in vitro susceptibility data in our study were 322 
developed following the same testing conditions as described in the CLSI M38-A2 document 323 
(21), a survey was sent to the 17 participant laboratories requesting the following information: (i) 324 
the source of the agents used; (ii) the formulation of the RPMI medium as described in the CLSI 325 
document; (iii) the cells (conidia versus yeasts) and count used to prepare the inoculum 326 
suspensions; and (iv) the growth inhibition criteria to determine MICs/MECs for each agent 327 
(including incubation temperature and length, and percentage of growth inhibition). The 328 
laboratories were also requested to provide MIC/MEC data for at least one of the QC or 329 
reference isolates (21).  330 
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Table 1. Pooled MIC distributions of four Sporothrix species from between 2 and 9 laboratories determined by CLSI M38-A2 broth microdilution method 478 




No. of isolates with MIC (µg/ml) of
a
 








S. schenckii*  9 263 2  5 9 29 100 78 33 3 1 3 








  3 5 8 19 29 6 3  2 
S. schenckii*  8 194  4 5 22 71 56 17 9 3 2 5 
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S. schenckii*    8 301  1 10 15 67 114 55 13 14 8 4 









































 S. brasiliensis 7 200     1 9 17 32 79 56 6 






















              
S. schenckii*  2 118 2 18 23 26 43 6      









The highest number in each row (showing the most frequently obtained MIC or the mode) is indicated in boldface.  480 
















Table 2. CLSI-ECVs for S. schenckii sensu stricto and S. brasiliensis based on MICs from between 3 and 9 laboratories by the CLSI broth 486 
microdilution method 487 
   MIC (µg/ml)a          ECVb 
Species  Antifungal agent No. of 
isolates 
tested 
Range Mode ≥ 95 % ≥97.5 %  
S. schenckii  Amphotericin B 263 0.03-32 1 4 4  
Itraconazole 194 0.06->32 0.5 2 2  
Ketoconazole ND c      
Posaconazole 301 0.06-16 1 2 4  
Voriconazole 252 0.5->32 16 64 64  
Terbinafine ND c      
        







































       
       
a Mode, most frequent MIC. 488 
bCalculated CLSI ECVs comprising >95 % and > 97.5 % of the statistically modeled population; values based on MICs determined by the 489 
CLSI M38-A2 broth dilution method (21). 490 
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